Yahoo•2026-04-23
Regeneron Shares Up on Trump Drug Pricing DealPFE — Pfizer Inc
NYSE · Pharmaceuticals · Pharmaceuticals
$26.67+3.17%Market cap155.12B
- Latest Close
- $26.67
- 30-Day Move
- +3.2%
- Market Cap
- $155.1B
- Shares Outstanding
- 5,688,360,000
- P/E Ratio
- 19.98
- P/B Ratio
- 1.64
Analyst consensus: Hold · 35 analysts
NYSE:PFEPharmaceuticals / PharmaceuticalsDelayed public snapshot
Pfizer Inc
A read-only Alphactor snapshot forPfizer Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$26.67
30-Day Move
+3.2%
Market Cap
$155.1B
Shares Outstanding
5,688,360,000
P/E Ratio
19.98
P/B Ratio
1.64
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$26.67
+3.2%last 90 delayed daily bars
Market cap$155.1B
90D High
$28.75
90D Low
$24.83
Avg Volume
43,973,334
What stands out
Gross margin is running at 75.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 12.4%, useful for comparing PFE against peers in Pharmaceuticals.
PFE is up 3.2% over the last 30 trading days shown on this page.
Latest operating income is $3.7B, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$21.84
Rule of 40
12.9%
Dark Pool Short %
41.1%
Fundamentals snapshot
Latest Close
$26.67
30-Day Move
+3.2%
Market Cap
$155.1B
Shares Outstanding
5,688,360,000
P/E Ratio
19.98
P/B Ratio
1.64
ROE
9.0%
ROA
3.7%
Gross Margin
75.8%
Operating Margin
15.4%
Net Margin
12.4%
Debt / Equity
0.75
Current Ratio
1.16
Dividend Yield
6.3%
Latest Revenue
$17.6B
Financial statement snapshot
Revenue
$17.6B
Gross Profit
$12.3B
Operating Income
$3.7B
Net Income
$-1.6B
Gross Margin
7581.0%
Net Margin
1242.0%
Current Ratio
1.16
Debt / Equity
0.75
Valuation snapshot
Fair Value
$21.84
Upside / Downside
-18.1%
Signal
Overvalued
Implied Growth
5.8%
DCF
$5.40
EPV
$16.15
EV/Rev
$43.96
Growth Assumption
-10.0%
Discount Rate
7.7%
Terminal Growth
2.0%
Base FCF
$9.1B
Valuation spread
Current Price
$26.67
Composite Fair Value
$21.84
DCF
$5.40
EPV
$16.15
EV/Rev
$43.96
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
2.15
Grey
Piotroski
6
Moderate (4-6)
Cash Conversion
1.51x
Rule of 40
12.9%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $101.2B | $38.1B | $31.4B | $26.0B |
| 2023-12-31 | $59.6B | $4.4B | $2.1B | $4.8B |
| 2024-12-31 | $63.6B | $14.9B | $8.0B | $9.8B |
| 2025-12-31 | $62.6B | $17.4B | $7.8B | $9.1B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Yahoo•2026-04-23
Novo Nordisk Expands GLP-1 Reach With Pediatric Oral Semaglutide DataYahoo•2026-04-23
Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?Yahoo•2026-04-23
Want $4,200 in Passive Income? Invest $90,000 ($30,000 Each) Into These 3 High-Yield Dividend StocksYahoo•2026-04-23
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q1 EarningsAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | BOURLA ALBERT | A | 22 | $27.19 |
| 2026-04-14 | BOURLA ALBERT | A | 911 | $27.11 |
| 2026-03-31 | BOURLA ALBERT | A | 21 | $28.08 |
| 2026-03-27 | Buckley Mortimer J | A | 1,387 | $27.04 |
| 2026-03-27 | Echevarria Joseph | A | 1,710 | $27.04 |
| 2026-03-27 | SMITH JAMES C | A | 1,664 | $27.04 |
| 2026-03-27 | Quincey James | A | 1,433 | $27.04 |
| 2026-03-27 | Taraporevala Cyrus | A | 1,387 | $27.04 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 178,794,865 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 143,372,214 | 0.03% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 72,357,758 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Core S&P 500 ETF | 72,479,712 | 0.01% | 2026-02-28 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 66,037,344 | 0.01% | 2026-03-31 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 52,323,615 | 0.01% | 2025-12-31 |
| SELECT SECTOR SPDR TRT-State Street Health Care Select Sector SPDR ETF | 41,556,698 | 0.01% | 2026-03-31 |
| VANGUARD INSTITUTIONAL INDEX FUNDS-Vanguard Institutional Index Fund | 32,629,910 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
T. Rowe Price
Filed 2025-11-14
--
--
Vanguard Group
Filed 2025-11-07
$13.6B
+0.2%
BlackRock
Filed 2024-05-10
$12.0B
--
Geode Capital Management
Filed 2025-11-12
$3.3B
+1.2%
Northern Trust
Filed 2025-11-14
$1.6B
+1.4%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.49
Consensus
HoldTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
35
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.